Ernexa Therapeutics Inc. · NASDAQ:ERNA
Ernexa Therapeutics — Eterna Therapeutics — Investor Presentation (November 2022)
15 slides from Ernexa Therapeutics's investor presentation, Nov 9, 2022
Slide 1: Eterna Therapeutics Company Overview November 2022
Eterna TherapeuticsCompany Overview November 2022 1 © Eterna Therapeutics Inc.
Slide 2: Legal notices and forward-looking statements
Legal notices This presentation (this “Presentation”) and any oral statements made in connection with this Presentation are for informational purposes only and do not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other securities
Slide 3: Eterna vision
Eterna vision We are a leading mRNA Cell Engineering platform based on a broad foundational intellectual property estate and will invest to realize its full potential We and our partners are discovering and developing an extraordinary breadth of valuable treatments to address some of the most fundam
Slide 4: The mRNA Cell Engineering platform
Eterna has exclusively in-licensed an extensive portfolio of patents broadly covering foundational mRNA Cell Engineering technologies We expect that Eterna’s patented technologies will be used in the most advanced cell engineering therapies in medicine We believe that Eterna’s established insiders a
Slide 5: $200B+ addressable market
$200B+ addressable market “mRNA: Therapeutics and Global Markets” (2021)https://www.bccresearch.com/market-research/biotechnology/mrna-vaccines-and-therapeutics-market.html “Global Cell Therapy And Tissue Engineering Market Size By Material (Biologically Derived, Synthetic), By Type (Cell Therapy, T
Slide 6: Core strategy: High-value strategic partnering
With over 100 foundational blocking in-licensed patents believed to cover both commercial and advanced clinical-stage products, Eterna is uniquely positioned to secure high-value strategic partnerships We have identified multiple $1bn+ market value public companies that we believe are currently usin
Slide 7: Cells are the building blocks of life
Cells contain DNA, which stores genetic information Every organ and every tissue is made of and made by cells Cells are the building blocks of life 7 © Eterna Therapeutics Inc. Disease is caused by damage to cells DNA is damaged by exposure to radiation, chemicals, and natural metabolism (aging)
Slide 8: Eterna's mRNA Cell Engineering Platform
Eterna’s mRNA Cell Engineering Platform ToRNAdo™ mRNA Delivery mRNAGene Editing mRNA mRNA Cell Reprogramming Eterna’s mRNA Cell Engineering platform addresses cellular dysfunction ToRNAdo™ mRNA Delivery enables in vivo repair of cellular dysfunction mRNA Gene Editing repairs genetic damage and confe
Slide 9: mRNA Cell Engineering can generate many valuable products across diverse modalities
mRNA Cell Engineering can generate many valuable products across diverse modalities Gene editing Gene replacement Cell replacement Blood cancers Solid tumors Ophthalmology Cardiology Neurology, etc. Many products Many products Many products Many products Many products Many products Eterna’s mRNA Cel
Slide 10: Technology partnership with Factor Bioscience
Technology partnership withFactor Bioscience Exclusive license to over 100 foundational mRNA Cell Engineering patents License grants Eterna the right to enforce these patents against third-party infringers Patent License Master Services Agreement 10 © Eterna Therapeutics Inc. Access to Factor’s rese
Slide 11: NK and T cell therapy partnership with Exacis Biotherapeutics
Eterna has secured an option to exclusively in-license up to four iPS cell-derived NK-cell and T-cell products which Eterna will develop for indications in oncology We believe that Exacis’ approach can target virtually any cancer antigen The NK cell market is expected to reach $5 billion by 20261 NK
Slide 12: Acute respiratory disease partnership with NoveCite Biotherapeutics
Eterna has partnered with NoveCite Biotherapeutics to develop an iPSC-derived cell therapy for the treatment of acute respiratory diseases First indication – Acute respiratory distress syndrome (ARDS) Award-winning presentation of large animal data at International Society of Cell & Gene Therapy 202
Slide 13: Leadership
Leadership Matt Angel, PhD Interim Chief Executive Officer Co-Founder & CEO, Factor Bioscience Co-Founder, Exacis Biotherapeutics Co-Founder, Novellus Therapeutics Andrew Jackson Chief Financial Officer Former CFO, Ra Medical Systems Former CFO, AltheaDx, Inc Former CFO, Celladon Corporation Roger S
Slide 14: Board of directors
Board of directors Charles Cherington Chairman Co-Founder, Ara Co-Founder, Intervale Capital Founder, Cherington Capital Matt Angel, PhD Interim Chief Executive Officer Co-Founder & CEO, Factor Bioscience Co-Founder, Exacis Biotherapeutics Founder, Novellus Therapeutics Gregory Fiore, MD Director CE
Slide 15: Slide 15
Eterna Therapeutics — Investor Presentation (November 2022) on 6ix